Contract manufacturer Norwich Pharma Services, which last year said it would be laying off about a fourth of its workforce, will now invest about $26 million in new equipment at its facility in Norwich, NY, according to the Press & Sun-Bulletin. VP Charlie Andrews said in a statement that the "investment will allow us to acquire equipment upon which many of the newer drug products are being manufactured." The company, part of Alvogen, makes DEA-scheduled products and intermediate potent compounds. The publication says that in November the company outlined plans to eliminate about 95 of the firm's 375-person workforce. Story